company background image
ATNX

AthenexNasdaqGS:ATNX Stock Report

Market Cap

US$361.8m

7D

-3.9%

1Y

-71.0%

Updated

23 Sep, 2021

Data

Company Financials +
ATNX fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

ATNX Overview

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer.

Price History & Performance

Summary of all time highs, changes and price drops for Athenex
Historical stock prices
Current Share PriceUS$3.42
52 Week HighUS$3.12
52 Week LowUS$15.00
Beta0.59
1 Month Change-1.16%
3 Month Change-32.68%
1 Year Change-71.04%
3 Year Change-77.98%
5 Year Changen/a
Change since IPO-72.77%

Recent News & Updates

Shareholder Returns

ATNXUS BiotechsUS Market
7D-3.9%0.07%-0.5%
1Y-71.0%31.0%37.5%

Return vs Industry: ATNX underperformed the US Biotechs industry which returned 28.4% over the past year.

Return vs Market: ATNX underperformed the US Market which returned 36.2% over the past year.

Price Volatility

Is ATNX's price volatile compared to industry and market?
ATNX volatility
ATNX Beta0.59
Industry Beta1.03
Market Beta1

Stable Share Price: ATNX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: ATNX's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2003599Johnson Lauhttps://www.athenex.com

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company’s Orascovery product candidates include Oral Paclitaxel, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignancies and gastric cancer; and Oral Irinotecan and Encequidar, a potent anticancer drug that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer.

Athenex Fundamentals Summary

How do Athenex's earnings and revenue compare to its market cap?
ATNX fundamental statistics
Market CapUS$361.81m
Earnings (TTM)-US$145.62m
Revenue (TTM)US$120.23m

3.1x

P/S Ratio

-2.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ATNX income statement (TTM)
RevenueUS$120.23m
Cost of RevenueUS$78.85m
Gross ProfitUS$41.39m
ExpensesUS$187.01m
Earnings-US$145.62m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.56
Gross Margin34.42%
Net Profit Margin-121.12%
Debt/Equity Ratio87.8%

How did ATNX perform over the long term?

See historical performance and comparison

Valuation

Is Athenex undervalued compared to its fair value and its price relative to the market?

2.02x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ATNX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ATNX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ATNX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: ATNX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ATNX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ATNX is good value based on its PB Ratio (2x) compared to the US Biotechs industry average (3.2x).


Future Growth

How is Athenex forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

31.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ATNX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ATNX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ATNX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ATNX's revenue (7.7% per year) is forecast to grow slower than the US market (9.8% per year).

High Growth Revenue: ATNX's revenue (7.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ATNX is forecast to be unprofitable in 3 years.


Past Performance

How has Athenex performed over the past 5 years?

-6.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ATNX is currently unprofitable.

Growing Profit Margin: ATNX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ATNX is unprofitable, and losses have increased over the past 5 years at a rate of 6.7% per year.

Accelerating Growth: Unable to compare ATNX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ATNX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).


Return on Equity

High ROE: ATNX has a negative Return on Equity (-87.05%), as it is currently unprofitable.


Financial Health

How is Athenex's financial position?


Financial Position Analysis

Short Term Liabilities: ATNX's short term assets ($213.1M) exceed its short term liabilities ($62.9M).

Long Term Liabilities: ATNX's short term assets ($213.1M) exceed its long term liabilities ($176.2M).


Debt to Equity History and Analysis

Debt Level: ATNX's debt to equity ratio (87.8%) is considered high.

Reducing Debt: ATNX's debt to equity ratio has increased from 27% to 87.8% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ATNX has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: ATNX has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of 20% each year.


Dividend

What is Athenex current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ATNX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ATNX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ATNX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ATNX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ATNX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.6yrs

Average management tenure


CEO

Johnson Lau (61 yo)

10.67yrs

Tenure

US$3,239,462

Compensation

Dr. Yiu-Nam Lau, also known as Johnson, MBBS, MD, FRCP, Ph D., has been the Chief Executive Officer of Athenex, Inc. since 2011. Dr. Lau is the Vice Chairman and CEO of Axis Therapeutics.Dr. Lau serves as...


CEO Compensation Analysis

Compensation vs Market: Johnson's total compensation ($USD3.24M) is above average for companies of similar size in the US market ($USD1.69M).

Compensation vs Earnings: Johnson's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: ATNX's management team is considered experienced (3.6 years average tenure).


Board Members

Experienced Board: ATNX's board of directors are considered experienced (3.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: ATNX insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.2%.


Top Shareholders

Company Information

Athenex, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Athenex, Inc.
  • Ticker: ATNX
  • Exchange: NasdaqGS
  • Founded: 2003
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$361.809m
  • Shares outstanding: 109.31m
  • Website: https://www.athenex.com

Number of Employees


Location

  • Athenex, Inc.
  • Conventus Building
  • Suite 600
  • Buffalo
  • New York
  • 14203
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/23 23:03
End of Day Share Price2021/09/23 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.